glioblastoma cells

[Nature] To systematically identify potential resistance pathways in an unbiased manner, scientists conducted a genome-wide CRISPR knockout screen in glioblastoma, a disease in which CAR T cells have had limited efficacy.

[Cell Death Discovery] Scientists observed that disrupting glioblastoma hyaluronic acid synthesis or blocking HA binding to its receptor CD44 on macrophages increased the proportion of M1 macrophages by upregulating SIRPα in macrophages,

[Cell Death & Disease] Researchers reported on the novel mechanism whereby overexpressed class I histone deacetylases increase the resistance of glioblastoma cells to the SN1 methylating agent temozolomide.

[Laboratory Investigation] Scientists treated glioblastoma cells with RSL3, a ferroptosis inducer, in vitro cell lines and in vivo subcutaneous and orthotopic animal models.

[Cancer Research] Researchers explored the potential of antisense oligonucleotides (ASO)-based pyruvate kinase (PKM) splice switching as a targeted therapy for liver cancer. A more potent lead constrained-ethyl/DNA ASO induced PKM splice switching and inhibited the growth of cultured HCC cells.

[Scientific Reports] Nine compounds demonstrated desirable glioblastoma cell toxicity in cell culture, and two of them, HR51, and HR59 demonstrated significantly improved capability of crossing the model blood–brain-barrier composed of endothelial cells, astrocytes and pericytes.